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Nonrandomized studies have a bad reputation in health care research. This is not 
entirely surprising: a key predictor of reversing established health care standards is the 
original adoption of an intervention on nonrandomized evidence alone.1 An earlier 
systematic evaluation found that several influential nonrandomized studies were refuted 
or found to have exaggerated effects when later tested in randomized controlled trials.2  
What should be done when randomization is not possible? In the linked article, 
Peng and colleagues evaluate the difference in wait times for receiving a donor heart 
between patients listed for a transplant before and after their 18th birthday and whether 
any difference in wait time is associated with lower likelihood of transplant and/or higher 
risk of mortality.3 It is not conceivable how a randomized controlled trial could be 
designed to address this important question.  
Fortunately, not all nonrandomized studies are created equal, and strong quasi-
experimental designs, when carefully used, can mimic randomization and produce valid 
findings.4 Peng and colleagues use one such quasi-experimental design – regression 
discontinuity design – and find that patients assigned after their 18th birthday to an adult 
allocation system had longer wait times and were less likely to receive a transplant than 
patients assigned before their 18th birthday to a paediatric allocation system, despite no 
observed differences in waitlist-associated mortality between the groups.  
When interpreting these findings, four questions are important to consider. First, 
why is randomization often considered essential to establish causality in health care 
research? Second, in its absence, what adjustment methods are available to “mimic” 
randomization and what are their drawbacks? Third, what are the assumptions of using 
quasi-experimental designs as substitutes to randomized controlled trials? Fourth, what 
specific issues arise in Peng and colleagues’ use of the regression discontinuity design? 
 
Why is randomization essential in health care research?  
Randomized controlled trials use a random process (e.g., a coin toss) to assign 
study subjects to different intervention groups. These so-called “gold-standard” designs 
ensure that the findings can be attributed to the intervention and nothing else. Random 
allocation introduces unpredictability to intervention assignment and reduces the 
likelihood that systematic differences in groups may influence outcomes.  
In nonrandomized designs, intervention assignment is deliberately influenced by 
the patient or the provider rather than randomly assigned by the researcher. This often 
results in differences in the baseline characteristics of patient groups receiving different 
interventions. In routine clinical practice, for instance, prescribing decisions may be 
guided by the prognosis of the patient: the worse the prognosis, the more intense the 
treatment.5 Therefore, in nonrandomized study designs, it is impossible to know if 
unknown or unmeasured factors that affect the outcomes of interest (e.g., indications for 
treatment, severity of illness) are evenly distributed across the intervention groups. Such 
differences are a severe threat to the validity of nonrandomized studies and explain why 
providers, researchers, and policy makers are often reluctant to use evidence from such 
designs to reach conclusions about the effect of interventions, programs, or policies.  
 
What analytic approaches are available to minimize differences between groups when randomization is 
not possible?  
When randomization is not possible to assign individuals to different groups, a 
range of alternative analytic strategies can be employed.6 Table 1 provides an overview of 
different adjustment methods and their advantages and disadvantages.  
Researchers often use standard regression methods to adjust for differences in 
baseline patient characteristics included in different groups. A key limitation of standard 
regression methods in nonrandomized designs is that they are strictly limited to known 
and measured variables in the data at hand.  
In recent years, a more advanced suite of analytic approaches has emerged. One 
such approach is propensity score matching. A propensity score expresses the probability 
of receiving a treatment based on a list of patient characteristics at the time of treatment 
initiation. Treatment effectiveness can then be measured among patients who have a 
similar (matched) propensity score, thus potentially controlling for confounding. While 
this approach can theoretically control for a large set of confounders,7 propensity score 
adjustment – like standard regression methods – cannot account for unknown or 
unmeasured factors and rarely addresses concerns in nonrandomized studies.8,9  
Another approach is instrumental variable analysis. Instrumental variable methods 
identify and exploit naturally occurring quasi-random events (referred to as 
“instruments”) that affect treatment assignment but does not otherwise affect outcomes, 
mimicking the randomization of patients into treatment.10 The validity of the 
instrumental variables approach depends on the researchers’ ability to assess whether the 
instrument chosen does not influence the outcome by any mechanism that is not 
mediated through the treatment – an assumption that is typically untestable using the 
data at hand.11 Despite this threat to the validity of nonrandomized studies using 
instrumental variables, the use of instrumental variables in health care research has 
skyrocketed in recent years.  
 
Table 1. Different analytic strategies 
Analytic strategy Advantages Disadvantages 
Standard regression 
analysis 
Introduces balance between 
groups on known and measured 
factors 
Unmeasured and unknown 
factors cannot be taken into 
account 
Propensity score 
adjustment 
Controls for larger numbers of 
known and measured factors than 
standard regression analysis 
Unmeasured and unknown 
factors cannot be taken into 
account 
Instrumental variable 
analysis 
Theoretically adjusts for known 
and unknown factors 
Assumptions are untestable 
with data at hand 
 
What are the assumptions of different nonrandomized designs as substitutes to randomized trials? 
In practice, testing the assumptions of different adjustment factors remain 
difficult. Previous empirical evaluations have warned against overreliance on such 
methods.12 Instead, researchers can adopt different nonrandomized, quasi-experimental, 
designs. Study designs that address issues of internal validity in the absence of 
randomization are referred to as “quasi-experimental” designs and include the controlled 
before-and-after design, interrupted time series analysis, and regression discontinuity 
design. Table 2 provides an overview of different quasi-experimental designs and their 
advantages and disadvantages. The rest of this commentary focuses on the regression 
discontinuity design used in the study by Peng and colleagues.  
Regression discontinuity designs are strong quasi-experimental designs that are 
increasingly used to evaluate the effect of clinical or policy decision rules based on 
specific eligibility criteria.13 Such decision rules are commonplace in clinical practice and 
health policy. Examples include LDL cholesterol thresholds for initiating statin therapy, 
income level for insurance coverage, and children’s date of birth for vaccination 
eligibility.  
These designs are particularly useful when people are differentially assigned to an 
intervention, program or policy if they fall below or above an arbitrary cut-off or 
threshold.14 In the study by Peng and colleagues, age serves as one such decision rule: 
patients awaiting heart transplants before or after their 18th birthdays are eligible for 
inclusion in different allocation systems and thus potentially different wait lists. The 
regression discontinuity design exploits this decision rule and assumes that patients 
whose age is “just above” (e.g., a few months older) or “just below” (e.g., a few months 
younger) this cut-off have similar characteristics. This is akin to considering the arbitrary 
cut-off as a quasi-random assignment to different groups. People who are just above the 
arbitrary cut-off are “randomly” assigned to one group while people who are just below 
the cut-off are assigned to another. The validity of findings obtained from studies 
employing regression discontinuity designs relies on the assumption that people around 
the cut-off are similar. In such designs, it is essential to perform robustness checks by 
differing the size of the comparison groups (by varying the distance from the cut-off) and 
reporting the sensitivity of the findings to different specifications. In theory, regression 
discontinuity designs have fewer assumptions than other quasi-experimental designs  
 
Table 2. Different quasi-experimental designs 
Quasi-
experimental 
design 
Description Assumptions Advantages Disadvantages 
Controlled before-
and-after design 
Outcomes are 
observed before 
and after an event 
of interest (e.g., 
intervention, 
program, policy) 
in two groups – 
only one group is 
exposed to the 
event 
Groups are similar 
on all known and 
unknown factors 
except for 
exposure to the 
event 
Feasible 
alternative when 
randomization is 
not possible 
Other factors 
could explain the 
observed changes 
in the outcome 
Interrupted time 
series analysis15 
When a key 
outcome is 
observed over a 
long period of 
time, slope and 
level of an 
outcome is 
compared before 
Observations after 
an event (e.g., 
intervention, 
program, policy) 
have a different 
slope or level 
from those before 
the event 
Pre-event time 
period serves as a 
strong internal 
control and 
addresses most 
threats to internal 
validity 
If there is an 
external event co-
occurring with the 
event under 
investigation, it 
may not be 
possible to 
attribute the 
and after an event 
of interest 
observed change 
in the outcome to 
either event 
Regression 
discontinuity 
design13 
Takes advantage 
of decision rules 
in which people 
are differentially 
assigned to an 
intervention if 
they fall below or 
above an arbitrary 
cut-off 
 
Groups with 
values “just 
above” and “just 
below” an 
arbitrary cut-off 
value are identical 
except for group 
allocation 
Mimics 
randomization 
around the 
arbitrary cut-off 
If group allocation 
around the 
“arbitrary” cut-off 
is not entirely 
arbitrary, groups 
may be 
systematically 
different from 
each other on 
factors that affect 
the outcome, 
leading to bias 
 
What specific issues arise in Peng and colleagues’ use of this design? 
Peng and colleagues admit that using regression discontinuity design was not their 
first choice and that they adopted this approach “[b]ecause of instability of the results 
using Cox regression when age was analysed as a dichotomous exposure variable using 
different age windows surrounding the 18th birthday.” Yet, the strength of the regression 
discontinuity design goes far beyond this issue: when used correctly, it can approximate 
random allocation of study subjects around an arbitrary cut-off.  
Still, if the key assumption of similarity around the decision cut-off is violated, 
findings of regression discontinuity designs may share the limitations of weaker 
nonrandomized alternatives. In the study by Peng and colleagues, if the decision to assign 
patients in late adolescence to adult vs. paediatric allocation systems is influenced by 
either patient or clinician factors, this could bias the results. If clinicians have a priori 
expectation that patients would have to wait longer on the adult allocation system, this 
might influence the listing time for patients approaching their 18th birthday. Such 
manipulation by clinicians would introduce systematic differences between patients just 
below and just above the cut-off, violating the key assumption of the regression 
discontinuity design. Study authors do not address this issue directly and in fact imply 
that this assumption may not hold in their analysis. There is also an apparent lack of 
sensitivity analyses to check the robustness of findings.  
 
Conclusion 
Regression discontinuity designs, despite their strengths, are underutilized in 
health care research.16 As Peng and colleagues highlight, their study is among the first 
applications of this method in cardiovascular medicine. Introducing an established quasi-
experimental method to an unfamiliar audience is no easy task. How do Peng and 
colleagues take up the challenge? Admittedly, they could do more to demystify the 
method and convincingly communicate and test for its assumptions. Substantially more 
robustness checks could go a long way to convince the reader that their findings stand to 
scrutiny.  
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